Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer

Hogg, SJ; Motorna, O; Kearney, CJ; Derrick, EB; House, IG; Todorovski, I; Kelly, MJ; Zethoven, M; Bromberg, KD; Lai, A; Beavis, PA; Shortt, J; Johnstone, RW; Vervoort, SJ

Author(s): Hogg, SJ; Motorna, O; Kearney, CJ; Derrick, EB; House, IG; Todorovski, I; Kelly, MJ; Zethoven, M; Bromberg, KD; Lai, A; Beavis, PA; Shortt, J; Johnstone, RW; Vervoort, SJ;
Details: Publication Year 2022-07-28,Volume 14,Issue #1,Page 96
Journal Title: Clinical Epigenetics
Abstract: BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated transcriptomic and epigenomic profiling to characterize the acute epigenetic changes induced by IFNγ stimulation in a murine breast cancer model. RESULTS: We identified de novo activation of cis-regulatory elements bound by Irf1 that were characterized by increased chromatin accessibility, differential usage of pro-inflammatory enhancers, and downstream recruitment of BET proteins and RNA polymerase II. To functionally validate this hierarchical model of IFNγ-driven transcription, we applied selective antagonists of histone acetyltransferases P300/CBP or acetyl-lysine readers of the BET family. This highlighted that histone acetylation is an antecedent event in IFNγ-driven transcription, whereby targeting of P300/CBP acetyltransferase activity but not BET inhibition could curtail the epigenetic remodeling induced by IFNγ through suppression of Irf1 transactivation. CONCLUSIONS: These data highlight the ability for epigenetic therapies to reprogram pro-inflammatory gene expression, which may have therapeutic implications for anti-tumor immunity and inflammatory diseases.
Publisher: BMC
Keywords: Bromodomain; Enhancer; H3k27ac; Histone acetylation; Immuno-oncology; Inflammation; Interferon; P300/cbp
Research Division(s): Epigenetics And Development
PubMed ID: 35902886
Publisher's Version: https://doi.org/10.1186/s13148-022-01316-5
Open Access at Publisher's Site: https://doi.org/10.1186/s13148-022-01316-5
Terms of Use/Rights Notice: Refer to copyright notice on published article.

Creation Date: 2023-02-02 02:06:29

Last Modified: 2023-02-02 02:10:43